Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;8(1):1-6.
doi: 10.1159/000494430. Epub 2018 Nov 22.

Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma

Affiliations

Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma

Nooshin Zargari et al. Eur Thyroid J. 2019 Jan.

Abstract

Objective: The diagnosis of thyroid tumors is based on histologic features, but the distinction between benign and malignant thyroid lesions is somehow difficult, especially in lesions with a follicular pattern. Thus, ancillary studies, such as immunohistochemistry (IHC), may be helpful. In this study, we aimed to evaluate the diagnostic value of 2 IHC markers, TROP-2 and HBME-1, in the diagnosis of thyroid cancers.

Study design: A total of 102 cases of thyroid lesions, including papillary thyroid carcinoma (classic variant) (29 cases), follicular variant of papillary thyroid carcinoma (21 cases), multinodular goiter (22 cases), follicular adenoma (24 cases), and follicular carcinoma (6 cases) were selected. The hematoxylin-eosin slides were reviewed for confirmation of diagnosis, and IHC examination for TROP-2 and HBME-1 was performed.

Result: HBME-1 had 84% sensitivity and 98% specificity with a positive predictive value (PPV) of 98% and a negative predictive value (NPV) of 83%. TROP-2 had 93% sensitivity and 74% specificity with a PPV of 81% and an NPV of 90% in malignant thyroid lesions.

Conclusion: IHC panel consisting of TROP-2 and HBME-1 can be used in equivocal follicular patterned lesions for the diagnosis of thyroid carcinomas.

Keywords: Follicular adenoma; Follicular carcinoma; HBME-1; Multinodular goiter; Papillary thyroid carcinoma; TROP-2; Thyroid.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a Hurthle cell adenoma, HE, ×400. b Negative for HBME-1. c Positivity for TROP-2 in Hurthle cells.
Fig. 2
Fig. 2
a Papillary thyroid carcinoma, HE, ×250. b Positive for HBME-1. c TROP-2 immunostaining.
Fig. 3
Fig. 3
a Follicular carcinoma with capsular invasion, HE, ×250. b Positive for HBME-1. c TROP-2 positivity.
Fig. 4
Fig. 4
a Follicular variant of papillary thyroid carcinoma, HE, ×400. b Positive for HBME-1. c TROP-2 positivity.
Fig. 5
Fig. 5
a Noninvasive follicular neoplasm with nuclear features of papillary thyroid carcinoma, HE, ×250. b Positive for HBME-1. c TROP-2 immunoreactivity.

Similar articles

Cited by

References

    1. Baloch ZW, Mack Harrell R, Brett EM, Randolph G, Garber JR. Managing thyroid tumors diagnosed as non-invasive follicular tumor with papilary like nuclear features. AACE. 2017 Sep;23((9)):1153–8. - PubMed
    1. Abd-El Raouf SM, Ibrahim TR. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. Pathol Res Pract. 2014 Dec;210((12)):971–8. - PubMed
    1. Liu H, Lin F. Application of immunohistochemistry in thyroid pathology. Arch Pathol Lab Med. 2015 Jan;139((1)):67–82. - PubMed
    1. Saleh HA, Jin B, Barnwell J, Alzohaili O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol. 2010 Jan;5((9)):9. - PMC - PubMed
    1. Paunovic I, Isic T, Havelka M, Tatic S, Cvejic D, Savin S. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors. APMIS. 2012 May;120((5)):368–79. - PubMed